Clinical outcomes of tebentafusp in metastatic uveal melanoma: a systematic review and single-arm meta-analysis - Takeaways - MDSpire

Clinical outcomes of tebentafusp in metastatic uveal melanoma: a systematic review and single-arm meta-analysis

  • By

  • Han Cai

  • Zhilong Huang

  • Bing-Long Wang

  • Ming Wei

  • Miao Tian

  • Hongmei Zheng

  • June 17, 2026

  • 0 min

Share

  • 1

    Tebentafusp shows a median overall survival of 21.3 months and progression-free survival of 3.6 months in metastatic uveal melanoma patients.

  • 2

    The objective response rate for tebentafusp is low at 9%, with 39% of patients achieving stable disease.

  • 3

    Cytokine release syndrome occurs in 88% of patients, with 2% experiencing grade 3 or higher severity.

  • 4

    Common adverse reactions include pyrexia (83%), nausea (58%), and fatigue (54%), which are generally manageable.

  • 5

    Further multi-center randomized controlled trials are needed to validate the findings and improve treatment strategies for metastatic uveal melanoma.

Original Source(s)

Clinical outcomes of tebentafusp in metastatic uveal melanoma: a systematic review and single-arm meta-analysis

  • by Han Cai, Zhilong Huang, Bing-Long Wang, Ming Wei, Miao Tian, Hongmei Zheng

  • June 17, 2026

Related Content

Case Report: Long-term maternal and neonatal outcomes after nivolumab therapy in metastatic tonsillar sarcomatoid squamous cell carcinoma

Revisiting gastric cancer disparities in Asian American subgroups: insights from the SEER database

Editorial: Innovative strategies in overcoming glioblastoma: advancements in treatment and research